180 related articles for article (PubMed ID: 29095297)
41. Transplantation-Associated Thrombotic Microangiopathy in Patients Treated With Sirolimus and Cyclosporine as Salvage Therapy for Graft-Versus-Host Disease.
García-Martín P; Alarcón-Payer C; López-Fernández E; Moratalla L; Romero A; Sainz J; Ríos R; Jurado M
Ann Pharmacother; 2015 Sep; 49(9):986-94. PubMed ID: 26160968
[TBL] [Abstract][Full Text] [Related]
42. Effect of acute graft-versus-host disease on the outcome of second allogeneic hematopoietic stem cell transplant in children.
Schechter T; Avila L; Frangoul H; Domm J; Dupuis LL; Naithani R; Zhao X; Pollock-Barziv S; Roifman C; Gassas A; Doyle J
Leuk Lymphoma; 2013 Jan; 54(1):105-9. PubMed ID: 22721498
[TBL] [Abstract][Full Text] [Related]
43. Clinical Features, Treatment, and Outcome of Pediatric Steroid Refractory Acute Graft-Versus-Host Disease: A Multicenter Study.
Verbeek AB; Jansen SA; von Asmuth EGJ; Lankester AC; Bresters D; Bierings M; Mohseny AB; Lindemans CA; Buddingh EP
Transplant Cell Ther; 2022 Sep; 28(9):600.e1-600.e9. PubMed ID: 35717003
[TBL] [Abstract][Full Text] [Related]
44. [Allogeneic hematopoietic stem cell transplantation for hemophagocytic syndrome].
Sun R; Xiao J; Zhang J; Lu Y; Wei Z; Zhu H; Sun Y
Zhonghua Er Ke Za Zhi; 2014 Feb; 52(2):94-8. PubMed ID: 24739718
[TBL] [Abstract][Full Text] [Related]
45. Enteric-coated mycophenolate sodium containing GvHD prophylaxis reduces GvHD rate after allogeneic HSCT.
Weber T; Niestadtkötter J; Wienke A; Müller-Tidow C; Müller LP
Eur J Haematol; 2016 Sep; 97(3):232-8. PubMed ID: 26613546
[TBL] [Abstract][Full Text] [Related]
46. Graft-Versus-Host Disease in Adolescents and Young Adults (15-24 Years Old) After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Leukemia in First Complete Remission.
Vignon M; Andreoli A; Dhédin N; Lengliné E; Masson E; Robin M; Granier C; Larghero J; Schlageter MH; de Latour RP; Socié G; Boissel N
J Adolesc Young Adult Oncol; 2017 Jun; 6(2):299-306. PubMed ID: 27983886
[TBL] [Abstract][Full Text] [Related]
47. Impact of graft-versus-host disease on the clinical outcome of allogeneic hematopoietic stem cell transplantation for non-malignant diseases.
Umeda K; Imai K; Yanagimachi M; Yabe H; Kobayashi M; Takahashi Y; Kajiwara M; Yoshida N; Cho Y; Inoue M; Hashii Y; Atsuta Y; Morio T;
Int J Hematol; 2020 Jun; 111(6):869-876. PubMed ID: 32052319
[TBL] [Abstract][Full Text] [Related]
48. A pilot study of tacrolimus and mycophenolate mofetil graft-versus-host disease prophylaxis in childhood and adolescent allogeneic stem cell transplant recipients.
Osunkwo I; Bessmertny O; Harrison L; Cheung YK; Van de Ven C; del Toro G; Garvin J; George D; Bradley MB; Wolownik K; Wischhover C; Levy J; Skerrett D; Cairo MS
Biol Blood Marrow Transplant; 2004 Apr; 10(4):246-58. PubMed ID: 15077223
[TBL] [Abstract][Full Text] [Related]
49. Relationship between cyclosporine area-under-the curve and acute graft versus host disease in pediatric patients undergoing hematopoietic stem cell transplant: A prospective, multicenter study.
Schechter T; Lewis VA; Schultz KR; Mitchell D; Chen S; Seto W; Teuffel O; Gibson P; Doyle JJ; Gassas A; Sung L; Lee Dupuis L
Pediatr Hematol Oncol; 2018 May; 35(4):288-296. PubMed ID: 30592246
[TBL] [Abstract][Full Text] [Related]
50. What is the outcome in patients with acute leukaemia who survive severe acute graft-versus-host disease?
Ringdén O; Labopin M; Sadeghi B; Mailhol A; Beelen D; Fløisand Y; Ghavamzadeh A; Finke J; Ehninger G; Volin L; Socié G; Kröger N; Stuhler G; Ganser A; Schmid C; Giebel S; Mohty M; Nagler A
J Intern Med; 2018 Feb; 283(2):166-177. PubMed ID: 29027756
[TBL] [Abstract][Full Text] [Related]
51. [Quadruple therapy with CsA, MTX, MMF and ATG for preventing graft-versus-host disease in unrelated donor hematopoietic stem cell transplantation].
Liu QF; Sun J; Zhang Y; Xu D; Liu XL; Xu B; Meng FY; Zhou SY
Di Yi Jun Yi Da Xue Xue Bao; 2003 Nov; 23(11):1143-5. PubMed ID: 14625172
[TBL] [Abstract][Full Text] [Related]
52. Feasibility of tacrolimus, methotrexate, and prednisolone as a graft-versus-host disease prophylaxis in non-T-cell-depleted haploidentical hematopoietic stem cell transplantation for children.
Mochizuki K; Kikuta A; Ito M; Sano H; Akaihata M; Kobayashi S; Ohto H; Hosoya M
Clin Transplant; 2011; 25(6):892-7. PubMed ID: 21070366
[TBL] [Abstract][Full Text] [Related]
53. [Induction of aGVHD after allogeneic hematopoietic stem cell transplantation for refractory or relapsed acute leukemia].
Sun J; Meng FY; Liu QF; Xu D; Xu B; Liu XL
Ai Zheng; 2003 Dec; 22(12):1321-4. PubMed ID: 14693060
[TBL] [Abstract][Full Text] [Related]
54. Impact of very early CD4(+) /CD8(+) T cell counts on the occurrence of acute graft-versus-host disease and NK cell counts on outcome after pediatric allogeneic hematopoietic stem cell transplantation.
Huttunen P; Taskinen M; Siitonen S; Saarinen-Pihkala UM
Pediatr Blood Cancer; 2015 Mar; 62(3):522-8. PubMed ID: 25417898
[TBL] [Abstract][Full Text] [Related]
55. Feasibility of extracorporeal photopheresis in pediatric patients with graft-versus-host disease after hematopoietic stem cell transplantation.
Winther-Jørgensen S; Nygaard M; Heilmann C; Ifversen M; Sørensen K; Müller K; Masmas T
Pediatr Transplant; 2019 Jun; 23(4):e13416. PubMed ID: 30973668
[TBL] [Abstract][Full Text] [Related]
56. Allogeneic human mesenchymal stem cell therapy (remestemcel-L, Prochymal) as a rescue agent for severe refractory acute graft-versus-host disease in pediatric patients.
Kurtzberg J; Prockop S; Teira P; Bittencourt H; Lewis V; Chan KW; Horn B; Yu L; Talano JA; Nemecek E; Mills CR; Chaudhury S
Biol Blood Marrow Transplant; 2014 Feb; 20(2):229-35. PubMed ID: 24216185
[TBL] [Abstract][Full Text] [Related]
57. Mortality, length of stay and costs associated with acute graft-versus-host disease during hospitalization for allogeneic hematopoietic stem cell transplantation.
Yu J; Parasuraman S; Shah A; Weisdorf D
Curr Med Res Opin; 2019 Jun; 35(6):983-988. PubMed ID: 30461314
[TBL] [Abstract][Full Text] [Related]
58. Low Counts of Plasmacytoid Dendritic Cells after Engraftment Are Associated with High Early Mortality after Allogeneic Stem Cell Transplantation.
Gonçalves MV; Yamamoto M; Kimura EY; Colturato VA; de Souza MP; Mauad M; Ikoma MV; Novis Y; Rocha V; Ginani VC; Wanderley de Oliveira Felix OM; Seber A; Kerbauy FR; Hamerschlak N; Orfao A; Rodrigues CA
Biol Blood Marrow Transplant; 2015 Jul; 21(7):1223-9. PubMed ID: 25792371
[TBL] [Abstract][Full Text] [Related]
59. Graft versus host disease in allogeneic stem cell transplantation--3 1/2 years experience.
Hashmi K; Khan B; Ahmed P; Hussain I; Altaf C; Raza S; Iqbal H; Khan MA; Malik HS; Naeem M; Kamal K; Anwar M
J Pak Med Assoc; 2005 Oct; 55(10):423-7. PubMed ID: 16304849
[TBL] [Abstract][Full Text] [Related]
60. Ruxolitinib for steroid-refractory graft versus host disease in pediatric HSCT: high response rate and manageable toxicity.
Mozo Y; Bueno D; Sisinni L; Fernández-Arroyo A; Rosich B; Martínez AP; Benítez-Carabante MI; Alonso L; Uría ML; Heredia CD; Mestre-Duran C; Pascual CFB; Torres J; Losantos I; Escudero A; Ruz-Caracuel B
Pediatr Hematol Oncol; 2021 May; 38(4):331-345. PubMed ID: 33661711
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
